ESC 2019 Guidelines — Supraventricular Tachycardia
2019 ESC Guidelines for the management of patients with supraventricular tachycardia
The 2019 guideline moved catheter ablation to first-line therapy for most symptomatic supraventricular tachycardias, which changes the shape of the answer in a large number of questions: the drug is the fallback, not the default.
Acute management is drug-specific and the wrong choices are named. Flecainide and propafenone are not for conversion of atrial flutter; amiodarone is not for pregnant patients; verapamil has no place when the mechanism of a broad complex tachycardia is unknown.
Pre-excitation carries its own recommendations for risk stratification and for the asymptomatic patient. Pregnancy has a defined drug hierarchy. And the patient who declines ablation, or in whom it carries an unacceptable risk of conduction block, is a recurring setup for the drug recommendations that remain.
What is in the bank
129 active questions. Class and level follow the recommendation each question is built from.